147 results about "Bevacizumab" patented technology

The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents (such as an anti-VEGF antibody), or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.

This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an anti-cancer agent which is an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) another anti-cancer agent. The other anti-cancer agent can be a platinum-based doublet chemotherapy, an EGFR-targeted tyrosine kinase inhibitor, bevacizumab, an anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) antibody, or any other therapy used to treat lung cancer in the art or disclosed herein.

Compositions which comprise a liposomal water-soluble camptothecin and optionally a liposomal fluoropyrimidine in combination with a vascular epithelial growth factor (VEGF) inhibitor such as cetuximab or an epidermal growth factor receptor (EGFR) inhibitor such as bevacizumab are useful in achieving enhanced therapeutic effects for the treatment of cancer.

This invention relates to the treatment of breast cancer in a subject, for example a female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer advanced breast cancer; breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and/or fulvestrant treatments; metastasis in a subject suffering from breast cancer; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.

The present invention provides small interfering RNA (siRNA) molecules, compositions containing the molecules, and methods of using the molecules and compositions to treat breast cancer. In one aspect, a multi-targeted siRNAi cocktail is disclosed. The siRNA molecules may be encapsulated in nanoparticles to further enhance their anti-cancer activity. The compositions may also be used in combination with other anti-cancer agents, such as bevacizumab.

Methods of treating cancer comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are provided. Dosage packs comprising an FGFR1 ECD and/or an FGFR1 ECD fusion molecule and/or at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are also provided. In some embodiments, a dosage pack comprises instructions for administering FGFR1 ECD and/or FGFR1 ECD fusion molecule with at least one additional therapeutic agent.

The present application relates to compositions of chimeric anti-endoglin antibodies and anti-VEGF agents. Another aspect relates to the use of chimeric anti-endoglin antibodies and Bevacizumab. Another aspect relates to the use of the compositions to inhibit VEGF induced sprouting. Another aspect relates to the use of the compositions to inhibit angiogenesis.

Methods for treating pterygium recurrence following pterygiectomy, and for treating keloid recurrence, following surgical removal of the keloid, are disclosed. The methods include administering an anti-VEGF agent (e.g., antibody (e.g., bevacizumab) or small molecule inhibitor of VEGF signaling), or a combination therapy that includes co-administering an anti-VEGF agent, with an anti-inflammatory steroid and/or a non-steroidal anti-inflammatory drug (NSAID) to a subject.

The present invention relates to a pharmaceutical composition, a kit and a method for treating cancer and/or a method for inhibiting angiogenesis, comprising a sulfonamide compound in combination with Bevacizumab.

Therapeutic combinations of immunoconjugates that bind to FOLR1 (e.g., IMGN853) with anti-VEGF agents (e.g., bevacizumab), a platinum-based agent, and/or doxorubicin are provided. Methods of administering the combinations to treat cancers, e.g., ovarian cancers, with greater clinical efficacy and/or decreased toxicity are also provided.

A magnetically controlled pump is implanted into the brain of a patient and delivers a plurality of medicating agents mixed with Avastin at a controlled rate corresponding to the specific needs of the patient. The current invention comprises a flexible double walled pouch that is formed from two layers of polymer. The pouch is alternately expanded and contracting by magnetic solenoid. When contracted, the medicating agent Avastin is pushed out of the pouch through a plurality of needles. When the pouch is expanded, surrounding cerebral fluid is drawn into the space between the double walls of the pouch from which it is drawn through a catheter to an analyzer. In cases where a tumor resection is not performed, an intratumoral catheter will be implanted. Cerebral fluid drawn from the patient is analyzed. The operation of the apparatus and hence the treatment is remotely controlled based on these measurements and displayed through an external controller.

The invention discloses a preparation method of long-acting sustained-release microspheres containing bevacizumab, which is a preparation method of the sustained-release microspheres formed by encapsulating water-soluble drug protein bevacizumab in a degradable biomedical polymer material. The microspheres are prepared by a W/O/W (water-in-oil-in-water) solvent evaporation method, which comprises the steps of: dispersing bevacizumab and a solution thereof and alginate as inner water phases into a solution which uses the degradable biomedical polymer material as an oil phase to form colostrum; dispersing the colostrum into an outer water phase which is water liquid containing emulsifier to form multiple emulsion; and stirring, distilling in reduced pressure, centrifuging, washing and drying to obtain the bevacizumab sustained-release microspheres. According to the long-acting sustained-release microspheres containing bevacizumab prepared by the method, the encapsulation efficiency of the water-soluble protein drug can be effectively improved, the drug protein activity is not influenced, the releasing time of water-soluble protein can be effectively prolonged, and the sustained release period can be 2-3 months, even longer, so that the number of injection times can be reduced. The preparation method is convenient for clinical application.

The present invention relates to compositions and methods for treating dry age related macular degeneration (dry AMD) by administration to an intraocular location of an anti-neovascular agent (such as bevacizumab) in either a liquid or solid polymeric vehicle (or both), such as a biodegradable hyaluronic acid or PLGA (or PLA).

The invention relates to a nanometer drug carrier (bevacizumab medicated-SiO2@LDH (sodium dioxide @ double hydroxide)) with an active tumor-targeting function, a preparation method and an application. The nanometer drug carrier uses mesoporous silica as a core, an outer layer is coated with magnesium-aluminum LDH, and the surface is connected with bevacizumab to form a nanometer compound. The nanometer drug carrier can be carried with a treatment drug; the purpose of tumor-targeting treatment is realized by recognizing the bevacizumab specificity and combining with the characteristics of VEGF (vascular endothelial growth factor) which is excessively secreted by tumors. The nanometer drug carrier has the advantages that the safety, active targeting property and drug carrying effect are higher; the synthesis method is simple, the cost is economic, and the application prospect in tumor-targeting treatment is broad.

The invention provides a method of inhibiting ocular neovascularization in a mammal by administering a composition comprising a bevacizumab-encoding adeno-associated virus (AAV) vector directly to the eye of the mammal.

Anti-angiogenic gene therapy with a combination of soluble Vascular Endothelial Growth Factors (sVEGFR) improves the efficacy of chemotherapy with paclitaxel for reducing ovarian cancer mean tumor volume (in cubic millimetres) as measured using magnetic resonance imaging. The study groups were: AdLacZ control, combination of AdsVEGFR-1, -2 and -3, combination of AdsVEGFR-1, -2, -3 and paclitaxel, bevacizumab monotherapy, paclitaxel monotherapy and carboplatin monotherapy. Effectiveness was assessed by survival time and surrogate measures such as sequential MRI, immunohistochemistry, microvessel density and tumor growth. Antiangiogenic gene therapy combined with paclitaxel significantly prolonged the mean survival compared to the controls and all other treatment groups (p=0.001). Tumors of the mice treated by gene therapy were significantly smaller than in the control group (p=0.021). The mean vascular density and total vascular area were also significantly smaller in the tumors of the gene therapy group (p=0.01).

The present application provides methods of treating a colon cancer (such as advanced and/or metastatic colon cancer) in an individual, comprising administering to the individual: a) an effective amount of a composition comprising nanoparticles comprising an mTOR inhibitor (such as a limus drug, such as sirolimus or a derivative thereof) and an albumin, b) an effective amount of anti-VEGF antibody (such as bevacizumab), and c) a therapeutically effective FOLFOX regimen (such as FOLFOX4 or a modified FOLFOX6).

Murine and humanized anti-human VEGF antibodies and uses are disclosed. The anti-human VEGF antibodies of the invention have higher binding affinity for human VEGF-A, are stronger inhibitors of the VEGF-A induced proliferation of endothelial cells in culture as compared with anti-human VEGF antibodies in the art. Moreover, these antibodies cross react with human VEGF-B. The antibodies of the invention inhibit tumor growth in vivo in greater extent than Bevacizumab (Avastin™) when administered at the same dosage

Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.

The invention belongs to the technical field of biological medicine, and particularly relates to a preparing method and medical application of optimized plant source recombination humanized bevacizumab. Heavy-chain and light-chain fusion protein of the recombinant antibody bevacizumab is expressed in plants, heavy chain and light chain are expressed in an proportion appropriate to 1:1 by adding 2A sequence to fusion protein, the proportion promotes assembly of a complete antibody obviously, and results show that the yield of antibodies expressed with the system is high. Meanwhile, due to the fact that a stable tetramer structure is formed through equal-proportion assembly of the heavy chain and light chain of the recombinant antibody, the number of unassembled polypeptides easy to degrade is reduced, and then pure and consistent monoclonal antibodies are obtained. The bevacizumab developed with a new method is applied to medicine to be used for treating breast cancer, lung cancer, spongioblastoma, kidney cancer, cervix uterus cancer, ovarian cancer, colon cancer and rectal cancer.